ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
Company profile
Ticker
OCGN
Exchange
Website
CEO
Shankar Musunuri
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
HISTOGENICS CORP
SEC CIK
Corporate docs
Subsidiaries
Ocugen Limited • Ocugen OpCo, Inc. • Histogenics Securities Corporation • Vaccigen Ltd. ...
OCGN stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
28 May 24
DEF 14A
Definitive proxy
28 May 24
PRE 14A
Preliminary proxy
17 May 24
8-K
Ocugen Provides Business Update with First Quarter 2024 Financial Results
14 May 24
10-Q
2024 Q1
Quarterly report
14 May 24
8-A12G
Registration of securities
10 May 24
8-K
Material Modifications to Rights of Security Holders
10 May 24
EFFECT
Notice of effectiveness
2 May 24
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Regulation FD Disclosure
29 Apr 24
Transcripts
OCGN
Earnings call transcript
2024 Q1
14 May 24
OCGN
Earnings call transcript
2023 Q4
2 Apr 24
OCGN
Earnings call transcript
2023 Q3
9 Nov 23
OCGN
Earnings call transcript
2023 Q2
22 Aug 23
OCGN
Earnings call transcript
2023 Q2
22 Aug 23
OCGN
Earnings call transcript
2023 Q1
5 May 23
OCGN
Earnings call transcript
2022 Q4
27 Feb 23
OCGN
Earnings call transcript
2022 Q3
8 Nov 22
OCGN
Earnings call transcript
2022 Q2
5 Aug 22
OCGN
Earnings call transcript
2022 Q1
7 May 22
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 26.38 mm | 26.38 mm | 26.38 mm | 26.38 mm | 26.38 mm | 26.38 mm |
Cash burn (monthly) | 4.36 mm | 3.49 mm | 4.07 mm | 4.98 mm | 3.53 mm | 4.53 mm |
Cash used (since last report) | 9.15 mm | 7.32 mm | 8.54 mm | 10.43 mm | 7.40 mm | 9.51 mm |
Cash remaining | 17.23 mm | 19.06 mm | 17.84 mm | 15.94 mm | 18.97 mm | 16.87 mm |
Runway (months of cash) | 3.9 | 5.5 | 4.4 | 3.2 | 5.4 | 3.7 |
Institutional ownership, Q4 2023
0.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 71 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 29.68 mm |
Total shares | 49.22 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Raymond James Financial Services Advisors | 22.92 k | $13.18 mm |
Wedmont Private Capital | 14.77 k | $9.60 mm |
Capital CS | 10.00 k | $5.75 mm |
CENTRAL TRUST | 500.00 | $288.00 k |
North Star Investment Management | 300.00 | $172.00 k |
Global Wealth Strategies & Associates | 300.00 | $173.00 k |
International Assets Investment Management | 230.00 | $400.00 k |
Versant Capital Management | 100.00 | $58.00 k |
Cedar Mountain Advisors | 100.00 | $58.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Apr 24 | Huma Qamar | Option Common Stock | Grant | Acquire A | No | No | 1.59 | 308,465 | 490.46 k | 308,465 |
3 Jan 24 | Musunuri Shankar | Common Stock | Payment of exercise | Dispose F | No | No | 0.653 | 180,204 | 117.67 k | 2,009,869 |
3 Jan 24 | Arun Upadhyay | Common Stock | Payment of exercise | Dispose F | No | No | 0.653 | 41,633 | 27.19 k | 349,589 |
2 Jan 24 | Musunuri Shankar | Option Common Stock | Grant | Acquire A | No | No | 0.6576 | 492,126 | 323.62 k | 492,126 |
News
(OCGN) - Analyzing Ocugen's Short Interest
31 May 24
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
17 May 24
Nayax Posts Weak Q1 Results, Joins GameStop, Iris Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
16 May 24
Chardan Capital Maintains Buy on Ocugen, Maintains $5 Price Target
15 May 24
4 Analysts Assess Ocugen: What You Need To Know
15 May 24
Press releases
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
2 Jun 24
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ocugen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
31 May 24
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
31 May 24
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
31 May 24
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
31 May 24